Enveric Biosciences, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ENVB Nasdaq 2834 www.enveric.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Enveric Biosciences, Inc.

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2024 - Mar 31st, 2025 12:00 pm
Enveric Biosciences Participating in BIO-Europe Spring® - Mar 17th, 2025 5:40 pm
Enveric Biosciences launches RFP solicitation process for PsyAI trademark - Mar 7th, 2025 3:05 pm
Enveric Biosciences Launches Request-For-Proposals Solicitation Process for PsyAI Trademark - Mar 6th, 2025 3:00 pm
Psychedelic: GH Research, Compass Pathways report earnings results - Feb 28th, 2025 4:30 pm
Enveric Biosciences CEO Issues Letter to Shareholders - Feb 27th, 2025 2:30 pm
Enveric Biosciences Unveils EVM401 Series of Compounds with New U.S. Patent - Feb 25th, 2025 6:30 pm
Enveric Biosciences and Restoration Biologics Announce Licensing Agreements to Treat Joint Disease - Feb 4th, 2025 1:00 pm
Enveric Biosciences Announces Closing of $5 Million Public Offering - Feb 3rd, 2025 10:00 pm
Enveric Biosciences Prices $5 Million Public Offering; Shares Drop 40% in Premarket Trading - Jan 31st, 2025 2:17 pm
Enveric Biosciences Announces Pricing of $5 Million Public Offering - Jan 31st, 2025 1:14 am
Enveric Biosciences Receives Notice of Allowance for Lead Drug Candidate EB-003 from United States Patent and Trademark Office - Jan 30th, 2025 9:01 pm
Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 8th Annual Neuroscience Innovation Forum During "J.P. Morgan Week 2025" - Jan 6th, 2025 2:10 pm
Enveric Biosciences Announces New U.S. Patents Supporting EVM301 Series and EVM201 Series Compounds - Dec 2nd, 2024 1:00 pm
Enveric Biosciences Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability, Demonstrate Brain Penetration, and Show No Evidence of Hallucination-like Behavior - Nov 25th, 2024 2:00 pm
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - Nov 18th, 2024 12:19 pm
Enveric Biosciences Reports Third Quarter 2024 Financial and Corporate Results - Nov 14th, 2024 9:05 pm
Enveric Biosciences Signs Out-Licensing Agreement with MycoMedica Life Sciences for EB-002 - Nov 12th, 2024 2:00 pm
Enveric Biosciences Announces Broad Range of Patent Issuances - Nov 4th, 2024 2:00 pm
Enveric Biosciences Announces Positive Pharmacology and Safety Data for Lead Product, EB-003 - Oct 15th, 2024 12:00 pm